Xilio Therapeutics Inc (XLO)
1.14
+0.06
(+5.56%)
USD |
NASDAQ |
May 17, 16:00
1.14
0.00 (0.00%)
After-Hours: 20:00
Xilio Therapeutics SG&A Expense (Quarterly): 6.139M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 6.139M |
| December 31, 2023 | 6.394M |
| September 30, 2023 | 6.31M |
| June 30, 2023 | 6.898M |
| March 31, 2023 | 7.395M |
| December 31, 2022 | 8.17M |
| September 30, 2022 | 7.168M |
| June 30, 2022 | 8.306M |
| Date | Value |
|---|---|
| March 31, 2022 | 6.304M |
| December 31, 2021 | 8.204M |
| September 30, 2021 | 5.491M |
| June 30, 2021 | 5.262M |
| March 31, 2021 | 4.899M |
| December 31, 2020 | 2.928M |
| September 30, 2020 | 3.163M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
2.928M
Minimum
Dec 2020
8.306M
Maximum
Jun 2022
6.202M
Average
6.31M
Median
Sep 2023
SG&A Expense (Quarterly) Benchmarks
| Gilead Sciences Inc | 1.375B |
| FibroGen Inc | 22.82M |
| Avalo Therapeutics Inc | 3.193M |
| IGM Biosciences Inc | 10.54M |
| AEON Biopharma Inc | -- |